Home / News / Pearce IP Blog
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 February 2025 are set out below:
In a split 3:2 decision, Gordon A-CJ, Edelman and Steward JJ of the High Court (the Majority) has dismissed the Commonwealth’s appeal in which the Commonwealth sought to overturn the decision of Justice Nicholas
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 February 2025 are set out below:
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
In October 2024, Delegate C. Mitchell of the Australian Patent Office upheld a decision to reject AFT Pharmaceuticals’ (AFT) drug combination patent applications – AU2022201576 (’576) and its divisional child
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
In a split 3:2 decision, Gordon A-CJ, Edelman and Steward JJ of the High Court (the Majority) has dismissed the Commonwealth’s appeal in which the Commonwealth sought to overturn the decision of Justice Nicholas
Justice Jackman of the Federal Court has refused to grant Virbac (Australia) Pty Ltd (Virbac) an interlocutory injunction to restrain Abbey Laboratories Pty Ltd (Abbey) from launching a generic version of Virbac’s Cydectic Platinum, used to treat and control parasites in beef and dairy cattle. Justice Jackman’s decision confirms the importance of not delaying when seeking injunctive relief, while also highlighting the relative difficulties faced by each party to quantify its potential losses.
The Full Federal Court has refused leave to appeal from costs orders made following the successful appeal in the long-running dispute between Vehicle Monitoring Systems (VMS), and SARB Management Group (SARB) and the City of Melbourne (CoM), over parking sensor technology.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 January 2025 are set out below:
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22 December 2024 to 17 January 2025 are set out below:
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22 December 2024 to 17 January 2025 are set out below:
In October 2024, the Intellectual Property Office of New Zealand (IPONZ) issued a decision concerning a patent application by Suntory Holdings Limited (Suntory) relating to the enhancement of sweetness in beverages using specific combinations of high-intensity sweeteners and sodium, while maintaining
The New Zealand Court of Appeal has handed down its second appeal decision in the long-running dispute between Sealegs International Limited and Anura Limited (formerly Orion Marine Limited) and
In a comprehensive Federal Court judgment, Justice Perram has ruled that pharmaceutical formulations can constitute a “pharmaceutical substance per se” under the Patents Act 1990 (Cth), dismissing Cipla’s
In a comprehensive Federal Court judgment, Justice Perram has ruled that pharmaceutical formulations can constitute a “pharmaceutical substance per se” under the Patents Act 1990 (Cth), dismissing Cipla’s